Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing targeted radiopharmaceutical therapies (TRT) against tumor targets. The company is focused on building a pipeline of advanced TRT products aimed at treating solid tumors. It plans to use the Series A proceeds to expand its leadership team, build radiopharmaceutical infrastructure, and secure strategic collaborations. Ablaze has a partnership with RayzeBio that grants it exclusive development and commercial rights to a series of RayzeBio’s products in the greater China region. Founded in 2021 and led by co-founder, President and CEO Dr. Alex Qiao, Ablaze operates out of Shanghai, China and San Diego, CA. The company raised $75M in a Series A financing to advance its clinical and commercialization efforts.

Total raised

$75M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2021